Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience by Aboud, Orwa et al.
RESEARCH ARTICLE Open Access
Apolipoprotein epsilon 3 alleles are associated
with indicators of neuronal resilience
Orwa Aboud
1,3, Robert E Mrak
4, Frederick Boop
5 and Sue T Griffin
1,2,3*
Abstract
Background: Epilepsy is associated with precocious development of Alzheimer-type neuropathological changes,
including appearance of senile plaques, neuronal loss and glial activation. As inheritance of APOE ε4 allele(s) is
reported to favor this outcome, we sought to investigate neuronal and glial responses that differ according to
APOE genotype. With an eye toward defining ways in which APOE ε3 alleles may foster neuronal well-being in
epilepsy and/or APOE ε4 alleles exacerbate neuronal decline, neuronal and glial characteristics were studied in
temporal lobectomy specimens from epilepsy patients of either APOE ε4,4 or APOE ε3,3 genotype.
Methods: Tissue and/or cellular expressions of interleukin-1 alpha (IL-1a), apolipoprotein E (ApoE), amyloid b (Ab)
precursor protein (bAPP), synaptophysin, phosphorylated tau, and Ab were determined in frozen and paraffin-
embedded tissues from 52 APOE ε3,3 and 7 APOE ε4,4 (0.25 to 71 years) epilepsy patients, and 5 neurologically
normal patients using Western blot, RT-PCR, and fluorescence immunohistochemistry.
Results: Tissue levels of IL-1a were elevated in patients of both APOE ε3,3 and APOE ε4,4 genotypes, and this
elevation was apparent as an increase in the number of activated microglia per neuron (APOE ε3,3 vs APOE ε4,4 =
3.7 ± 1.2 vs 1.5 ± 0.4; P < 0.05). This, together with increases in bAPP and ApoE, was associated with apparent
neuronal sparing in that APOE ε4,4 genotype was associated with smaller neuron size (APOE ε4,4 vs APOE ε3,3 =
173 ± 27 vs 356 ± 45; P ≤ 0.01) and greater DNA damage (APOE ε4,4 vs APOE ε3,3 = 67 ± 10 vs 39 ± 2; P = 0.01).
3) Ab plaques were noted at early ages in our epilepsy patients, regardless of APOE genotype (APOE ε4,4 age 10;
APOE ε3,3 age 17).
Conclusions: Our findings of neuronal and glial events, which correlate with lesser neuronal DNA damage and
larger, more robust neurons in epilepsy patients of APOE ε3,3 genotype compared to APOE ε4,4 genotype carriers,
are consistent with the idea that the APOE ε3,3 genotype better protects neurons subjected to the hyperexcitability
of epilepsy and thus confers less risk of AD (Alzheimer’s disease).
Please see related article: http://www.biomedcentral.com/1741-7015/10/36
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Background
Epilepsy is associated with precocious development of
Alzheimer-type neuropathological changes, and the
APOE ε4 genotype has been associated with further risk
of development of such changes [1,2]. A role for glial
activation with excess expression of cytokines in epilepsy
pathogenesis was first recognized as enlargement of
microglia and astrocytes with overexpression of IL-1
and S100B, respectively [3-5]. Such findings gave rise to
a new understanding of the role of glial activation and
overexpression of cytokinesa sp o t e n t i a lp r e c u r s o r so f
neurodegenerative change, including Ab plaques and
neurofibrillary tangles [6]. These findings are consistent
with the idea that glia-related neuroinflammatory events
are early contributors to epilepsy pathogenesis.
Neuronal stress, such as the hyperexcitability induced by
glutamate in epilepsy, elevates neuronal expression of
bAPP and release of sAPP, which activates microglia and
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any medium, provided the original work is properly cited.induces excess IL-1 production. This elevation in IL-1 pro-
duction is attenuated by ApoE 3, but not ApoE 4 [7]. In
turn, IL-1 induces further neuronal expression of bAPP
and sAPP leading to further microglial activation and
further release of IL-1 [8]. IL-1 also induces neuronal
expression of ApoE [9], which in turn induces further
expression of bAPP in an ApoE isoform-dependent man-
ner; with ApoE3 more effective than ApoE4 [10].
A great deal of research has been dedicated to under-
standing how and why the presence of an APOE ε4
allele(s) is so strongly associated with negative outcomes
in neurological conditions, such as head injury [11].
Here, rather than taking this tack, we chose to investi-
gate the potential for beneficial effects conferred by
APOE ε3 alleles due to their neuroprotective potential.
Tissue samples from temporal lobes resected from epi-
lepsy patients carrying two APOE ε3 alleles were exam-
ined regarding an association between inheritance of
these alleles and determinants of neuronal resilience.
These determinants included the ability of neurons to
mount appropriate acute phase responses, including
increases in bAPP and ApoE, as well as management of
DNA damage, maintenance of morphological integrity
and glial activation. Our findings indicate that the APOE
ε3,3 genotype confers a neuroprotective advantage over
the APOE ε4,4 genotype, in the setting of intractable
epilepsy with its accompanying hyperexcitability-induced
neuronal damage, glial activation and excessive expres-
sion of the proinflammatory cytokine IL-1a.
Methods
Patients and specimens
Resected temporal lobe tissues were obtained from 95
epilepsy patients; of those 59 were included in this study
(39 males and 20 females; 52 APOE ε3,3 and 7 APOE
ε4,4) with an age at surgery ranging from 0.25 to 71
years. Analyses of surgical waste remains from temporal
lobectomy surgeries to treat intractable, drug-resistant
epilepsy were compared to those of autopsy samples
from neurologically normal individuals brought to
autopsy for reasons other than this study. Both surgical
waste and autopsy tissue are exempt under 46.101 5(b)
and approved by our University of Arkansas Institu-
tional Review Board.
All patients underwent anterior temporal lobectomy
for treatment of medication-resistant intractable epi-
lepsy. Tissue was sectioned at 4 mm intervals and alter-
nate sections were preserved by flash freezing for
molecular analyses and by formalin fixation for histolo-
gical evaluation. Preliminary immunohistochemical ana-
lysis was performed on all epilepsy cases, and a smaller
group was selected for further investigation. Six APOE
ε3,3 cases (five males and one female, ages 18, 24, 38,
44, 67 and 57 years, respectively) and four APOE ε4,4
cases (three males and one female, ages 10, 22, 50 and
34, respectively) were selected for more extensive ana-
lyses, based on age in the case of APOE ε3,3 patients,
and with regard to availability of sufficient frozen tissue
for molecular analyses among APOE ε4,4 patients. Suffi-
cient frozen tissue and fixed tissue was available for
both immunohistochemical and molecular analyses of
four APOE ε4,4 patients (three males and one female,
ages as above). For uniformity, immunohistochemical
examination was restricted to cortical layers III, IV, V
and VI of the superior temporal lobe. For comparison of
results from our APOE ε3,3 and APOE ε4,4 genotype
patients, analogous temporal lobe tissues from neurolo-
gically normal individuals of varying APOE genotype
and at older ages (four males and one female, ages 71,
97, 59, 50 and 93 years) were assessed. This selection
was based on the premise that individuals with pre-AD
(Alzheimer’s disease) or with AD at these ages would
have plaques.
Reagents
The antibodies used were as follows: rabbit anti-human
IL-1a (Peprotech, Rocky Hill, NJ, USA, 4:1,000); goat
anti-human APOE (Life Technology, Grand Island, NY,
USA, 1:50); mouse anti-human Ab/bAPP (Covance,
Denver, CO, USA, 1:1,000); rabbit anti-synaptophysin
(Abcam, Cambridge, MA, USA, 1:1,000); rabbit anti-
phosphorylated tau (Abcam 1:3,000); rabbit anti-actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA,
1:5,000) were diluted in antibody diluent (DAKO, Car-
penteria, CA, USA), and Iba-1 (WAKO, Richmond, VA,
USA,1:400). Mounting media containing Prolong Gold
antifade reagent with DAPI (Life Technologies) was
used to stain nuclei.
Immunohistochemistry
Paraffin-embedded tissue was sectioned at 7 μm, depar-
affinized in xylene and rehydrated in graduated ethanol
solutions to deionized water. Sections for IL-1a immu-
noreaction were placed in boiling sodium citrate buffer
(0.01 M, pH 6.0) for 20 minutes; sections for bAPP and
ApoE were placed in trypsin solution for 10 minutes at
37°C, and all were blocked using protein block (DAKO),
a n di n c u b a t e do v e r n i g h ta tr o o mt e m p e r a t u r e .S e c o n d -
ary antibodies, Alexa Fluor donkey anti-goat and donkey
anti-rabbit were diluted in antibody diluent (DAKO)
and sections were incubated for 60 minutes, washed
three times for 5 minutes each in distilled H2O, and
coverslipped with prolong Gold with DAPI.
Plaque analysis
Plaques were identified by the simultaneous presence of
ApoE and Ab immunoreactivity. The number of plaques
in 10 consecutive 20X images (0.37 mm
2) from sections
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phase was based on Braak and Braak staging of Ab pla-
ques [12] and estimated with regard to our experience
with such estimation in Alzheimer tissue.
Image analysis
Similar to a previous study [10], a quantitative approach
was used to examine the number of glia and neurons.
Three images per slide (40X magnification) were cap-
tured at identical exposure settings, using a Nikon
Eclipse E600 microscope (Melville, NY, USA) equipped
with a Coolsnap ES monochrome camera (Photometrics,
T u c s o n ,A Z ,U S A ) .E a c ho ft h et h r e ei m a g e s ,s p a n n i n g
37,241.5 μm
2, was acquired and analyzed using NIS-Ele-
ments BR3 software http://Nikon.com and thresholded.
Only microglia immediately adjacent to neuron somas
were counted. Data were analyzed by ANOVA to assess
difference among groups. Significance was provided by
P ≤ 0.05.
Reverse transcription (RT) reaction and polymerase chain
reaction (PCR) amplification
Total RNA was extracted from brain tissue using TriRea-
gent™ RNA (Molecular Research Center, Cincinnati, OH,
USA) according to the manufacturer’s instructions. RT-
PCR was performed as previously described [9]. Briefly, for
comparisons of mRNA levels among different RNA sam-
ples, RT reactions were performed simultaneously using
reagents from a single master mix. PCR was performed
using reagents from Clontech (Mountain View, CA, USA).
The sequences of primers for human IL-1a and GAPDH,
amplification cycles and annealing temperature are pro-
vided in Table 1. PCR reactions were stopped by incuba-
tion for 10 minutes at 72°C. Equal volumes of reaction
mixture from each sample were loaded onto 1.2% agarose
gels, and fluorescent images were digitally captured for
analysis of intensity with NIH Image software 1.60 version
http://rsbweb.nih.gov/nih-image/. Levels of IL-1a were
normalized relative to GAPDH in the same sample.
Western immunoblot assay
Proteins were extracted from brain tissue in a lysis buffer
comprising 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1%
Nonidet P40, 1 mM EGTA, 1 mM EDTA and 1% sodium
deoxycholate; lysates were quantified using a Micro BCA
assay reagent kit (Pierce, Rockford, IL, USA) as described
previously [13]. Aliquots (50 μg each) were loaded onto 4
to 12% Criterion
XT precast Gels (Biorad, Hercules, CA,
USA, Catalog # 345-0123), subjected to electrophoresis
at 90 V for 1.5 h, and transferred to nitrocellulose mem-
branes. Blots were blocked in I-Block Buffer (Applied
Biosystem Inc., Bedford, MA, USA) for 60 minutes, then
incubated overnight at 4°C with either goat polyclonal
antibody anti-IL-a (Santa Cruz Biotechnology 1:500),
mouse anti-human Ab/bAPP (Covance 1:1,000), rabbit
anti-synaptophysin (Abcam 1:1,000), rabbit anti-phos-
phorylated tau (Abcam 1:3,000), or rabbit anti-actin
(Santa Cruz Biotechnology 1:5,000); the latter of which
was used here for calculating the relative levels of the
other proteins assessed by western blot analyses. Mem-
branes were then incubated for 1 h at room temperature
with alkaline phosphatase-conjugated secondary antibody
and developed using the Western-Light™ Chemilumi-
nescent Detection System (Applied Biosystem Inc., Bed-
ford, MA, USA). Autoradiographs were digitized and
analyzed using NIH Image software, version 1.60.
TUNEL staining procedure
For terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) (NeuroTacs Kit, 4823-30-K, Tre-
vigen, Gaithersburg, MD, USA) reactions, rehydrated
sections were permeablized with NeuroPore
® for 30
minutes at room temperature, washed in PBS buffer,
placed in TdT labeling buffer for 5 minutes, treated
with the labeling reaction mix (TdT dNTP, 50 × Mn
+2,
and TdT Enzyme) for 60 minutes at 37°C followed by
stop buffer for 5 minutes, then streptavidin AF 594 con-
jugate (Invitrogen, S32356) for 10 minutes at room tem-
perature. The sections were then treated with 0.1%
Sudan black B in 70% ethanol for two minutes to block
lipofuscin autofluorescence, washed in three changes of
distilled H2O, five minutes each; and coverslipped with
Prolong Gold with DAPI.
Statistical analysis
Data were analyzed using an unpaired t-test, and values
were considered significantly different when the P-value
was ≤ 0.05. Results are expressed as mean ± SD.
Results
Numbers of IL-1a-immunoreactive microglia per neuron
are APOE genotype-dependent
An initial screening of 59 epilepsy patients (52 APOE
ε3,3;7APOE ε4,4) and 5 neurologically normal controls
Table 1 Human gene sequences for IL-1a and GAPDH,











IL-1a F: AAG CCT TCC TGC CGC AAC 57 32
R: CTG CAC CTA CCA AAC ACG
G
GAPDH F: AGG TCG GAG TCA ACG GAT
TTG
57 32
R: TGG CAG GTT TTT CTA GAC
GGC
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Page 3 of 10revealed an observable elevation in numbers of microglia
per neuron soma in brain tissue from epilepsy patients
compared to that in brain tissue from controls (data not
shown). A smaller group of age-matched patients with
either APOE ε3,3 (n = 6) or APOE ε4,4 (n = 4) genotype
was chosen for further analysis to determine if this
increase in numbers of IL-1a immunoreactive microglia
(Iba-1-immunoreactive) per ApoE-immunoreactive neu-
ron segregated according to APOE genotype. Numbers
as high as 8 IL-1a/Iba-1-immunoreactive microglia were
noted clustered immediately adjacent to individual
ApoE-immunoreactive neurons in APOE ε3,3 patients
(Figure 1A) compared to a maximum of three microglia
per neuron in APOE ε4,4 patients (Figure 1B). Overall,
APOE ε3,3 neurons had twice as many associated micro-
glia as did APOE ε4,4 neurons (3.7 ± 1.2 vs 1.5 ± 0.4; P
< 0.01) (Figure 1C). As to the total number of microglia
per 0.037 mm
2 in tissue from epilepsy patients with
APOE ε3,3 vs APOE ε4,4 genotype (37.2 ± 10.6 vs 23 ±
5.7; P < 0.05).
Neuron number and size with regard to APOE genotype
To assess the consequences of epilepsy and APOE geno-
type on neurons, we counted neurons in cortical layers
III to VI of three specific areas of the temporal lobe. By
histological inspection, changes in the appearance of
individual neurons were evident, with the distinguishing
feature being an APOE ε4,4 genotype-associated
decrease in size of both the cytoplasm and nucleus (Fig-
ure 2A, B). When quantified, this general impression
correlated with a genotype-related difference in neuronal
size. The average size of neurons in patients with APOE
ε4,4, was smaller than in patients with APOE ε3,3 (173
±2 7v s3 5 6±4 5μm
2; P < 0.001) (Figure 2C, D), but
the numbers of neurons were not different in cortical
layers of patients with APOE ε4,4 and APOE ε3,3 geno-
types (24 ± 2 vs 22 ± 3; P = 0.18) (Figure 2E, F),.
Neuronal DNA damage is related to APOE genotype
DNA damage was present in similar numbers of neu-
rons in analogous areas of the temporal lobe, without
regard to APOE genotype (Figure 3A, C). However, the
extent of damage per neuron, as assessed by TUNEL
fluorescence intensity, was greater in patients with
APOE ε4,4 than with APOE ε3,3 genotype (67 ± 10 vs
39 ± 2; P = 0.01) (Figure 3B, D).
bAPP tissue levels as a function of IL-1a expression and
APOE genotype
The increased numbers of microglia per neuron noted
in APOE ε3,3 vs APOE ε4,4 patients were reflected at
the level of IL-1a synthesis and production. Overall,
levels of IL-1a mRNA were elevated within a group of
10 of our epilepsy patients with various combinations of
APOE ε2, APOE ε3,o rAPOE ε4 alleles compared to
levels in control patients (Figure 4A), although one
patient with APOE ε4,4 genotype had mRNA levels that
were not different from that of control patients (Figure
4B). Overall, patients with epilepsy had IL-1a mRNA
levels that were five-fold higher than those of
Figure 1 Microglial numbers per neuron in epilepsy relative to APOE genotype IL-1a-immunoreactive microglia (green) clustered
around individual ApoE-immunoreactive neuron soma (red) in a 21-year-old APOE ε3,3 (A) and a 34-year-old APOE ε4,4 (B) patient.A
maximum of 8 microglia per neuron were present in APOE ε3,3 patients compared to four or fewer in APOE ε4,4 patients (C). Overall, APOE ε3,3
patients had twice as many microglia per neuron as did APOE ε4,4 patients. Nuclei were stained with DAPI (blue). White arrows denote neurons
with microglia.
Aboud et al. BMC Medicine 2012, 10:35
http://www.biomedcentral.com/1741-7015/10/35
Page 4 of 10Figure 2 Neuron size and number in epilepsy relative to APOE genotype An apparent larger size of neurons (arrows) in patients with
APOE ε3,3 (A) relative to those in patients with APOE ε4,4 (B) genotype was confirmed by computer assisted area measurements of
individual neurons (APOE ε3,3 = 356 ± 45 μm
2 vs APOE ε4,4 = 173 ± 27 μm
2; P < 0.001) (C and D). However, the numbers of neurons per
image were similar for both genotypes (APOE ε3,3 = 21.5 ± 3.1 vs APOE ε4,4 = 24.0 ± 1.8; P = 0.18) (E and F).
Figure 3 Neuronal DNA damage in epilepsy relative to APOE genotype Neurons with nuclear DNA damage were present in similar
numbers in analogous areas of temporal lobe for both APOE genotypes (A and C). However, the extent of damage per neuron, as
assessed by semi-quantitative analysis of TUNEL fluorescence intensity (arbitrary units, au) in these areas, was greater in patients with APOE ε4,4
than in those with APOE ε3,3 genotype (APOE ε4,4 = 67.1 ± 9.5 vs APOE ε3,3 = 39.2 ± 2.3; P = 0.01) (B and D). TUNEL labeling (red) and DAPI
nuclear staining (blue).
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Page 5 of 10neurologically normal controls. In contrast to the epi-
lepsy-associated increase in IL-1a mRNA in patients of
both genotypes, IL-1a protein measured by Western
blot showed much greater elevation of IL-1a protein in
APOE ε3,3 patients than that in APOE ε4,4 patients
(Figure 4C). The increased IL-1a expression in APOE
ε3,3 patients was approximately four-fold that of APOE
ε4,4 patients (APOE ε3,3 = 51 ± 29 vs APOE ε4,4 = 9±
4; control 6 ± 1; P < 0.01) (Figure 4D). These elevations
in the levels of both IL-1a mRNA and protein were
accompanied by an APOE ε3,3 genotype-specific
increase in bAPP expression in epilepsy patients com-
pared to controls (APOE ε3,3 = 42 ± 11 vs APOE ε4,4 =
20 ± 11; and control = 21 ± 7; P = 0.03) (Figure 4E, F).
Ab and ApoE deposition relative to APOE genotype
We found Ab neuritic plaques in 13 of 52 APOE ε3,3
patients, including one who was only 17 years old; one of
the 7 APOE ε4,4 patients had plaques; the youngest, 10
years of age (Figure 5A-C). For this one APOE ε4,4 patient,
the number of plaques observed was 17, which was similar
to that found in four APOE ε3,3 patients who had Ab pla-
ques, numbering 11, 15, 14 and 16. Interestingly, the Ab
plaque phase in the one APOE ε4,4 patient was dense core
neuritic while the plaques in APOE ε3,3 patients did not
have dense cores. With our limited number of patients
with APOE ε4,4 genotype, it is not possible to say whether
a specific APOE genotype is associated with either a higher
probability of having plaques or a genotype-related earlier
age of onset for such Ab plaques. However, epilepsy was
associated with an increased probability of Ab plaque
development at a very early age. All Ab plaques observed
contained ApoE deposits as well as ApoE-immunoreactive
neurites, without regard to age or gender.
Neuronal expression of ApoE is related to APOE genotype
In addition to ApoE immunoreactivity in Ab plaques
and in Ab plaque-associated neurites in tissue from epi-
lepsy, ApoE expression was also evident in neurons in
all regions examined without regard to the presence of
Ab plaques. Semi-quantitative ApoE immunofluores-
cence intensity in neuronal somas was elevated in those
with APOE ε3,3 genotype relative to those with APOE
ε4,4 genotype (APOE ε3,3 =1 0±1v sAPOE ε4,4 =8 . 3
±0 . 8 ;P < 0.05) (Figure 5D). This modest elevation in
immunofluorescence intensity was paralleled in APOE
ε3,3 p a t i e n t sb yam a r k e di n c r e a s ei nr e l a t i v et i s s u e
levels (Figure 5E) of ApoE (APOE ε3,3 =7 . 1 9±1 . 7 5v s
APOE ε4,4 = 1.04 ± 0.06, and control = 1.27 ± 0.38; P <
0.001) (Figure 5F).
Figure 4 Neural cell acute phase responses in epilepsy relative to APOE genotype IL-1a mRNA levels in temporal lobe tissue from
epilepsy patients were elevated compared to levels in control patients (A). With the exception of one patient with APOE ε4,4 genotype,
patients with epilepsy had mRNA levels that were greater than those of control patients (B). By Western blot (C), the relative levels of IL-1a
protein from epilepsy patients with APOE ε3,3 were four-fold higher (51 ± 29) than those from either epilepsy patients with APOE ε4,4 genotype
(8.6 ± 4.3) or those of neurologically normal controls (6.3 ± 1.2; P = 0.01 for all comparisons) (D). These elevations in both IL-1a mRNA and
protein levels were accompanied by an increase in bAPP expression (E) that was limited to APOE ε3,3 patients (APOE ε3,3 = 42 ± 11 vs APOE ε4,4
= 20 ± 11 and control = 21 ± 7; P = 0.03 for all comparisons) (F).
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Page 6 of 10Synaptophysin and phosphorylated tau expression
relative to APOE genotype
The synaptic density in photomicrographs from each of
the patient groups appeared to be similar, with some-
what higher levels in those with APOE ε3,3 genotype, as
measured by relative levels of synaptophysin (APOE ε3,3
= 3.57 ± 0.76 vs APOE ε4,4 = 2.62 ± 0.80 vs controls =
2.41 ± 0.36; P = 0.11) (Figure 6A. B). As previously
reported [14], phosphorylated tau immunofluorescent
labeling was not elevated in any of our patients regard-
less of age or ApoE genotype. This was confirmed by
Western blot analysis; the bands were faint and the
measured levels were low (Figure 6C, D).
Discussion
Tissues from patients undergoing temporal lobectomies
for drug-resistant epilepsy reveal APOE genotype-speci-
fic links between glial and neuronal stress responses.
This influence of APOE genotype in epilepsy appears to
occur without regard to gender or age at the time of
surgery. Glial activation with overexpression of IL-1 is
w e l lk n o w nt oi n d u c en e u r o n a le x p r e s s i o no ft w oA D -
associated, stress-related proteins ApoE and bAPP
[10,15]. Connections among APOE genotype, epilepsy
and AD have been drawn, but mechanisms by which the
APOE ε4,4 genotype heightens intensity of neuronal
damage or, conversely, how the APOE ε3,3 genotype
may act to promote neuronal resilience remains unclear.
The numbers of neurons in temporal lobe tissue of
our epilepsy patients who were either APOE ε3,3 or
APOE ε4,4 genotype were similar, but there were strik-
ing differences in the indicators of degeneration in neu-
rons, as neurons from patients with APOE ε3,3 were
larger, appeared more normal morphologically, and had
less DNA damage. These findings suggest that neurons
from individuals with the APOE ε3,3 genotype are better
able to mount appropriate and more liberal repair
responses to the damaging hyperexcitability of epilepsy
than are their APOE ε4,4 counterparts, suggesting that
APOE ε3,b u tn o tAPOE ε4, alleles confer resilience to
Figure 5 ApoE tissue levels and Ab p l a q u e si ne p i l e p s yr e l a t i v et oA P O Eg e n o t y p eM u l t i p l eA b (green) and ApoE (red)
immunofluorescent plaques were present in 15 of the 52 APOE ε3,3 patients (colocalization of ApoE and Ab is yellow). (A)
Representative section from a 30-year-old APOE ε3,3 patient. (B) Representative section from the one of seven APOE ε4,4 patients who had Ab
plaques. (C) Both the shape and distribution to Ab plaques were similar without regard to APOE genotype as shown in a 24-year-old APOE ε3,3
patient illustrated by light microscopy (ApoE immunoreactivity (brown); Ab (magenta)). (D) ApoE immunofluorescent intensity was greater in
tissue from those with APOE ε3,3 than in those with APOE ε4,4 genotype (APOE ε3,3 =1 0±1v sAPOE ε4,4 = 8.3 ± 0.8; P = 0.04). This difference
in intensity was paralleled by increased relative tissue levels of ApoE (E) (APOE ε3,3 = 7.19 ± 1.75 vs APOE ε4,4 = 1.04 ± 0.06, and control = 1.27
± 0.38; P < 0.001 for all comparisons) (F).
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be inferred from studies reporting earlier onset of epi-
lepsy, especially following traumatic brain injury in
patients with APOE ε4 alleles [16,17].
Our finding of elevated synthesis of IL-1a in the tem-
poral lobe of epilepsy patients compared to that in neu-
rologically normal controls confirms an earlier report
[4] of elevated IL-1a protein and accompanying glial
activation and other neuroinflammatory changes. How-
ever, the association made here between this overexpres-
sion of IL-1a and beneficial effects toward enhancing
neuronal resilience may help to explain, at least in part,
why IL-1a elevation is necessary for neuronal survival in
dorsal root ganglion cell cultures [18]. Moreover, evi-
dence of greater neuron sparing in epilepsy patients
with APOE ε3,3 than APOE ε4,4 genotype may be a case
in point for genetic variation favoring typical, evolutio-
narily old, acute phase responses [19] of neurons to
adverse stimuli, which includes elevation of IL-1a, bAPP
and ApoE expression [10] and protection against DNA
fragmentation.
The original report of a role for IL-1a in induction,
maintenance and propagation of axonal sprouting in an
experimental model of neurodegeneration [20] and an
association between glial activation and sprouting of
mossy fibers in epilepsy [21] is supported by our finding
of somewhat elevated synaptophysin levels in combina-
tion with high numbers of neuron-associated, IL-1a
immunoreactive microglia and elevation of IL-a mRNA
and protein levels. In addition, the apparent elevation of
synaptophysin expression noted here in immunoblots of
neural tissue proteins from our epilepsy patients com-
pared to that from our neurologically and neuropatholo-
gically normal controls may be explained if, as
previously noted in animal models of epilepsy, [21,22]
there is neuronal sprouting in epilepsy patients.
Amyloid-b plaques are obligatory for the diagnosis of
AD and are most prominent in the elderly. In contrast, Ab
plaques in epilepsy, as shown here and as reported in
about 10% of cases [2], are evident at young ages. For
instance among our patients, a 10-year-old patient had
Ab/ApoE immunoreactive plaques in a distribution similar
to that noted in temporal lobes of Alzheimer patients. The
presence of plaques at such early ages suggests that they
are harbingers of impending neurodegeneration and AD.
Although the number of plaques was similar in tissue
from our patients without regard to APOE genotype, in
our one APOE ε4,4 patient the developmental phase of Ab
plaques appeared to be advanced relative to those
observed in our APOE ε3,3 patients – our APOE ε4,4
Figure 6 Synaptophysin, phosphorylated tau and actin in epilepsy relative to APOE genotype An impression of similar synaptic
densities in photomicrographs from each of the patient groups was confirmed by western blot analysis for the relative levels of
synaptophysin compared to actin (APOE ε3,3 =3 .57 ± 0.76 vs APOE ε4,4 = 2.62 ± 0.8 vs controls = 2.41 ± 0.36; P = 0.11 for all comparisons)
(A and B). Western blot analysis of phosphorylated tau (P-tau) (C) showed no differences with regard to genotype (D). Western blot analysis of
actin (E) was used to assess specific protein levels of IL-1a, bAPP, ApoE, synaptophysin, and P-tau relative to actin. Actin expression was not
different with regard to APOE genotype or levels of actin in tissue from controls (F).
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Page 8 of 10patient had dense core neuritic Ab plaques, while such
dense core plaques were not found among the plaques
observed in our APOE ε3,3 patients. This observation is
consistent with the possibility that the phase of Ab plaque
progression is accelerated in those with APOE ε4,4 geno-
type and supports the findings of Marz et al., regarding
t h er o l eo fAPOE genotype in the onset of Ab plaque
pathology and the presence of dense core plaques [23].
Alzheimer’s patients are more likely to have seizures
than are those in the general population [24]. This,
together with our findings and the previously reported
preferential occurrence of seizures in younger Alzheimer
patients [25], supports a suggested relationship between
the high levels of Ab in the brains of epilepsy patients [26]
and increased risk for development of AD. These findings
are consistent with the idea that AD-related neuronal
stress and its sequelae, including excess neuronal bAPP
and ApoE expression and glial activation with elevated
cytokine expression, combined with known IL-1-driven
elevation of neuronal and glial glutamate production con-
tribute to the hyperexcitability of epilepsy [9]. Moreover,
these findings, together with evidence from our epilepsy
patients, suggest that ApoE genotype, in particular APOE
ε4,4 may favor rapidity of disease progression as well as
risk for associated memory disturbances. Conversely, a
better understanding of mechanisms by which APOE ε3
alleles confer the neuronal protection shown here may
facilitate development of therapeutic strategies toward
improving outcomes for epilepsy patients, as well as
patients with other neuronal distresses.
Conclusion
T h em o s ts t r i k i n ga s p e c to ft h i sw o r ki st h a to u rf i n d -
ings illuminate the “other” side of the APOE genotypic
equation in showing ways in which APOE ε3 alleles may
act to preserve important aspects of neuronal abilities to
mount appropriate, beneficial stress responses to hyper-
excitability, neuroinflammation and neuronal DNA
damage. In addition, our findings are consistent with
the idea that as neurons with APOE ε4 alleles are less
resilient to the chronic excitation of epilepsy and more
susceptible to DNA damage, patients who carry APOE
ε4 alleles are at greater risk of developing AD than are
those with APOE ε3 alleles. Moreover, our findings are
in accord with the possibility that epilepsy-related neu-
ropathological changes, such as increases in the levels of
Ab peptides, contribute to propagation of epileptiform
activity in adjacent neurons and furtherance of neuro-
pathological changes and the risk of AD [26].
Abbreviations
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